Risk Factors and Prevention in Light of Atherosclerosis Being a Microvascular Disease



Accumulating evidence demonstrates that dysfunctional microvasculature contributes to localized inflammation that precipitates site-specific plaque formation. Given the importance of the blood vessel wall microvasculature in atherosclerosis disease development, we examine how risk factors might contribute to both vasa vasorum and lymphatic dysfunction. In addition, we discuss how microcirculatory endothelium, even more than the parent vessel endothelium, is a likely beneficiary of current common preventative measures and therapies. Therefore, this chapter makes a strong case for impaired microcirculation being a unifying factor underlying many atherosclerosis risk factors.


Atherosclerosis Microvasculature Vasa vasorum Microthrombosis Risk factors Endothelial regeneration Endothelial repair Neutrophil extracellular traps Platelet activation Microbiota Statins Exercise 


  1. 1.
    Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res. 1980;47:301–11. Scholar
  2. 2.
    Sepúlveda C, Palomo I, Fuentes E. Primary and secondary haemostasis changes related to aging. Mech Ageing Dev. 2015;150:46–54. Scholar
  3. 3.
    Sepúlveda C, Palomo I, Fuentes E. Mechanisms of endothelial dysfunction during aging: predisposition to thrombosis. Mech Ageing Dev. 2017;164:91–9. Scholar
  4. 4.
    Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol. 2006;16:123–30. Scholar
  5. 5.
    Reilly IAG, FitzGerald GA. Eicosenoid biosynthesis and platelet function with advancing age. Thromb Res. 1986;41:545–54. Scholar
  6. 6.
    Kasjanovová D, Baláz V. Age-related changes in human platelet function in vitro. Mech Ageing Dev. 1986;37:175–82.CrossRefGoogle Scholar
  7. 7.
    Zahavi J, Jones NA, Leyton J, et al. Enhanced in vivo platelet “release reaction” in old healthy individuals. Thromb Res. 1980;17:329–36.CrossRefGoogle Scholar
  8. 8.
    Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380–5.PubMedGoogle Scholar
  9. 9.
    Favaloro EJ, Soltani S, McDonald J, et al. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol. 2005;124:910–7.CrossRefGoogle Scholar
  10. 10.
    Shahidi M. Thrombosis and von Willebrand factor. Adv Exp Med Biol. 2017;906:285–306. Scholar
  11. 11.
    Blann AD, Bushell D, Davies A, et al. von Willebrand factor, the endothelium and obesity. Int J Obes Relat Metab Disord. 1993;17:723–5.PubMedGoogle Scholar
  12. 12.
    Ma W-H, Sheng L, Gong H-P, et al. The application of vWF/ADAMTS13 in essential hypertension. Int J Clin Exp Med. 2014;7:5636–42.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626–30.CrossRefGoogle Scholar
  14. 14.
    Blann AD. Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb. 2003;33:256–61. Scholar
  15. 15.
    Lufkin EG, Fass DN, O’Fallon WM, Bowie EJ. Increased von Willebrand factor in diabetes mellitus. Metabolism. 1979;28:63–6.CrossRefGoogle Scholar
  16. 16.
    Kessler L, Wiesel ML, Attali P, et al. Von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998;24:327–36.PubMedGoogle Scholar
  17. 17.
    Seligman BG, Biolo A, Polanczyk CA, et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23:1395–400.CrossRefGoogle Scholar
  18. 18.
    Mousa SA. Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin. Int Angiol. 2005;24:278–81.PubMedGoogle Scholar
  19. 19.
    Patel SR, Bellary S, Karimzad S, Gherghel D. Overweight status is associated with extensive signs of microvascular dysfunction and cardiovascular risk. Sci Rep. 2016;6:32282. Scholar
  20. 20.
    Holvoet P, Donck J, Landeloos M, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996;76:663–9.CrossRefGoogle Scholar
  21. 21.
    Vianello F, Cella G, Osto E, et al. Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? Am J Hematol. 2015;90:109–13. Scholar
  22. 22.
    Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: a meta-analysis of prospective evidence. Hypertension. 2010;55:1026–32. (Dallas, Tex 1979).CrossRefGoogle Scholar
  23. 23.
    Wilbert-Lampen U, Leistner D, Greven S, et al. Cardiovascular events during World Cup soccer. N Engl J Med. 2008;358:475–83. Scholar
  24. 24.
    Lin H, Young DB. Opposing effects of plasma epinephrine and norepinephrine on coronary thrombosis in vivo. Circulation. 1995;91:1135–42.CrossRefGoogle Scholar
  25. 25.
    Ramadan R, Sheps D, Esteves F, et al. Myocardial ischemia during mental stress: role of coronary artery disease burden and vasomotion. J Am Heart Assoc. 2013;2:e000321. Scholar
  26. 26.
    Dakak N, Quyyumi AA, Eisenhofer G, et al. Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. Am J Cardiol. 1995;76:125–30.CrossRefGoogle Scholar
  27. 27.
    Arrighi JA, Burg M, Cohen IS, et al. Myocardial blood-flow response during mental stress in patients with coronary artery disease. Lancet (London, England). 2000;356:310–1. Scholar
  28. 28.
    Born GV, Shafi S, Cusack NJ. Evidence for the acceleration of atherogenesis by circulating norepinephrine. Transplant Proc. 1989;21:3660–1.PubMedGoogle Scholar
  29. 29.
    Shafi S, Cusack NJ, Born GV. Increased uptake of methylated low-density lipoprotein induced by noradrenaline in carotid arteries of anaesthetized rabbits. Proc R Soc Lond Ser B Biol Sci. 1989;235:289–98. Scholar
  30. 30.
    Cardona-Sanclemente LE, Born GV. Adrenaline increases the uptake of low-density lipoproteins in carotid arteries of rabbits. Atherosclerosis. 1992;96:215–8.CrossRefGoogle Scholar
  31. 31.
    Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–5. Scholar
  32. 32.
    Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci. 2012;109:13076–81. Scholar
  33. 33.
    Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880–5. Scholar
  34. 34.
    Etulain J, Martinod K, Wong SL, et al. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015;126:242–6. Scholar
  35. 35.
    Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science. 2015;349:316–20. Scholar
  36. 36.
    Megens RTA, Vijayan S, Lievens D, et al. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost. 2012;107:597–8. Scholar
  37. 37.
    Riegger J, Byrne RA, Joner M, et al. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J. 2016;37:1538–49. Scholar
  38. 38.
    de Boer O, Li X, Teeling P, et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost. 2013;109:290–7. Scholar
  39. 39.
    Döring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120:736–43. Scholar
  40. 40.
    Schröder AK, Rink L. Neutrophil immunity of the elderly. Mech Ageing Dev. 2003;124:419–25.CrossRefGoogle Scholar
  41. 41.
    Martinod K, Witsch T, Erpenbeck L, et al. Peptidylarginine deiminase 4 promotes age-related organ fibrosis. J Exp Med. 2017;214:439–58. Scholar
  42. 42.
    Awasthi D, Nagarkoti S, Kumar A, et al. Oxidized LDL induced extracellular trap formation in human neutrophils via TLR-PKC-IRAK-MAPK and NADPH-oxidase activation. Free Radic Biol Med. 2016;93:190–203. Scholar
  43. 43.
    Qiu S-L, Zhang H, Tang Q-Y, et al. Neutrophil extracellular traps induced by cigarette smoke activate plasmacytoid dendritic cells. Thorax. 2017;72:1084–93. Scholar
  44. 44.
    Wang H, Wang Q, Venugopal J, et al. Obesity-induced endothelial dysfunction is prevented by neutrophil extracellular trap inhibition. Sci Rep. 2018;8:4881. Scholar
  45. 45.
    Kim J-K, Hong C-W, Park MJ, et al. Increased neutrophil extracellular trap formation in uremia is associated with chronic inflammation and prevalent coronary artery disease. J Immunol Res. 2017;2017:8415179. Scholar
  46. 46.
    Wang Y, Xiao Y, Zhong L, et al. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with -cell autoimmunity in patients with type 1 diabetes. Diabetes. 2014;63:4239–48. Scholar
  47. 47.
    Menegazzo L, Ciciliot S, Poncina N, et al. NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetol. 2015;52:497–503. Scholar
  48. 48.
    Fadini GP, Menegazzo L, Rigato M, et al. NETosis delays diabetic wound healing in mice and humans. Diabetes. 2016;65:1061–71. Scholar
  49. 49.
    Menegazzo L, Scattolini V, Cappellari R, et al. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018;55:593–601. Scholar
  50. 50.
    Park SK, Adar SD, O’Neill MS, et al. Long-term exposure to air pollution and type 2 diabetes mellitus in a multiethnic cohort. Am J Epidemiol. 2015;181:327–36. Scholar
  51. 51.
    Krämer U, Herder C, Sugiri D, et al. Traffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study. Environ Health Perspect. 2010;118:1273–9. Scholar
  52. 52.
    Weinmayr G, Hennig F, Fuks K, et al. Long-term exposure to fine particulate matter and incidence of type 2 diabetes mellitus in a cohort study: effects of total and traffic-specific air pollution. Environ Heal. 2015;14:53. Scholar
  53. 53.
    Coogan PF, White LF, Jerrett M, et al. Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. Circulation. 2012;125:767–72. Scholar
  54. 54.
    Clark C, Sbihi H, Tamburic L, et al. Association of long-term exposure to transportation noise and traffic-related air pollution with the incidence of diabetes: a prospective cohort study. Environ Health Perspect. 2017;125:087025. Scholar
  55. 55.
    Killin LOJ, Starr JM, Shiue IJ, Russ TC. Environmental risk factors for dementia: a systematic review. BMC Geriatr. 2016;16:175. Scholar
  56. 56.
    Chen H, Kwong JC, Copes R, et al. Exposure to ambient air pollution and the incidence of dementia: a population-based cohort study. Environ Int. 2017;108:271–7. Scholar
  57. 57.
    Tzivian L, Dlugaj M, Winkler A, et al. Long-term air pollution and traffic noise exposures and mild cognitive impairment in older adults: a cross-sectional analysis of the Heinz Nixdorf recall study. Environ Health Perspect. 2016;124:1361–8. Scholar
  58. 58.
    Robertson S, Miller MR. Ambient air pollution and thrombosis. Part Fibre Toxicol. 2018;15:1. Scholar
  59. 59.
    Hajat A, Allison M, Diez-Roux AV, et al. Long-term exposure to air pollution and markers of inflammation, coagulation, and endothelial activation: a repeat-measures analysis in the Multi-Ethnic Study of Atherosclerosis (MESA). Epidemiology. 2015;26:310–20. Scholar
  60. 60.
    Jacobs L, Emmerechts J, Mathieu C, et al. Air pollution related prothrombotic changes in persons with diabetes. Environ Health Perspect. 2010;118:191–6. Scholar
  61. 61.
    Cozzi E, Wingard CJ, Cascio WE, et al. Effect of ambient particulate matter exposure on hemostasis. Transl Res. 2007;149:324–32. Scholar
  62. 62.
    Radomski A, Jurasz P, Alonso-Escolano D, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146:882–93. Scholar
  63. 63.
    Ghio AJ, Hall A, Bassett MA, et al. Exposure to concentrated ambient air particles alters hematologic indices in humans. Inhal Toxicol. 2003;15:1465–78. Scholar
  64. 64.
    Lucking AJ, Lundback M, Mills NL, et al. Diesel exhaust inhalation increases thrombus formation in man. Eur Heart J. 2008;29:3043–51. Scholar
  65. 65.
    Lucking AJ, Lundbäck M, Barath SL, et al. Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men. Circulation. 2011;123:1721–8. Scholar
  66. 66.
    Nemmar A, Hoylaerts MF, Hoet PHM, Nemery B. Possible mechanisms of the cardiovascular effects of inhaled particles: systemic translocation and prothrombotic effects. Toxicol Lett. 2004;149:243–53. Scholar
  67. 67.
    Wu S, Deng F, Wei H, et al. Chemical constituents of ambient particulate air pollution and biomarkers of inflammation, coagulation and homocysteine in healthy adults: a prospective panel study. Part Fibre Toxicol. 2012;9:49. Scholar
  68. 68.
    Franchini M, Capra F, Targher G, et al. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007;5:14. Scholar
  69. 69.
    Smith NL, Chen M-H, Dehghan A, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121:1382–92. Scholar
  70. 70.
    Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost. 2003;1:2191–7.CrossRefGoogle Scholar
  71. 71.
    Song J, Chen F, Campos M, et al. Quantitative influence of ABO blood groups on factor VIII and its ratio to von Willebrand factor, novel observations from an ARIC study of 11,673 subjects. PLoS ONE. 2015;10:e0132626. Scholar
  72. 72.
    Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–5.PubMedGoogle Scholar
  73. 73.
    He M, Wolpin B, Rexrode K, et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol. 2012;32:2314–20. Scholar
  74. 74.
    Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:62–9. Scholar
  75. 75.
    Tanis B, Algra A, van der Graaf Y, et al. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol. 2006;77:67–73. Scholar
  76. 76.
    Kole TM, Suthahar N, Damman K, De Boer RA. ABO blood group and cardiovascular outcomes in the general population: a meta-analysis. Eur J Hear Fail. 2017;19:175.Google Scholar
  77. 77.
    Horne BD, Muhlestein JB, Carlquist JF, et al. Interaction of genetic variation in the ABO locus and short-term exposure to elevations in fine particulate matter air pollution differentially affects associations with acute coronary events. Am Hear Assoc Sci Sess Meet Anaheim, CA;2017.Google Scholar
  78. 78.
    Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161:264–76. Scholar
  79. 79.
    Jäckel S, Kiouptsi K, Lillich M, et al. Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2. Blood. 2017;130:542–53. Scholar
  80. 80.
    Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165:111–24. Scholar
  81. 81.
    Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated trimethylamine n-oxide from dietary choline is prothrombotic in subjects. Circulation. 2017;135:1671–3. Scholar
  82. 82.
    Seldin MM, Meng Y, Qi H, et al. Trimethylamine N-Oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5.
  83. 83.
    Brown JM, Hazen SL. Microbial modulation of cardiovascular disease. Nat Rev Microbiol. 2018;16:171–81. Scholar
  84. 84.
    Klein LW. Cigarette smoking, atherosclerosis and the coronary hemodynamic response: a unifying hypothesis. J Am Coll Cardiol. 1984;4:972–4.CrossRefGoogle Scholar
  85. 85.
    Brook RD, Brook JR, Urch B, et al. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation. 2002;105:1534–6.CrossRefGoogle Scholar
  86. 86.
    Goel A, Su B, Flavahan S, et al. Increased endothelial exocytosis and generation of endothelin-1 contributes to constriction of aged arteries. Circ Res. 2010;107:242–51. Scholar
  87. 87.
    Donato AJ, Gano LB, Eskurza I, et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2009;297:H425–32. Scholar
  88. 88.
    Weil BR, Westby CM, Van Guilder GP, et al. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol. 2011;301:H689–95. Scholar
  89. 89.
    Westby CM, Weil BR, Greiner JJ, et al. Endothelin-1 vasoconstriction and the age-related decline in endothelium-dependent vasodilatation in men. Clin Sci (Lond). 2011;120:485–91. Scholar
  90. 90.
    Van Guilder GP, Stauffer BL, Greiner JJ, Desouza CA. Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists. Am J Physiol Heart Circ Physiol. 2008;294:H1685–92. Scholar
  91. 91.
    Schinzari F, Iantorno M, Campia U, et al. Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2015;309:E787–92. Scholar
  92. 92.
    Langrish JP, Lundbäck M, Mills NL, et al. Contribution of endothelin 1 to the vascular effects of diesel exhaust inhalation in humans. Hypertens. 2009;54:910–5. (Dallas, Tex 1979).CrossRefGoogle Scholar
  93. 93.
    Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999;100:820–5.CrossRefGoogle Scholar
  94. 94.
    Cardillo C, Kilcoyne CM, Cannon RO, Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol. 2000;36:1483–8.CrossRefGoogle Scholar
  95. 95.
    Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783–7.CrossRefGoogle Scholar
  96. 96.
    Xie Y, Fan Y, Xu Q. Vascular regeneration by stem/progenitor cells. Arterioscler Thromb Vasc Biol. 2016;36:e33–40. Scholar
  97. 97.
    Lee PSS, Poh KK. Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells. 2014;6:355–66. Scholar
  98. 98.
    Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600. Scholar
  99. 99.
    Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111:2981–7. Scholar
  100. 100.
    Werner N, Wassmann S, Ahlers P, et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary artery disease. Basic Res Cardiol. 2007;102:565–71. Scholar
  101. 101.
    O’Toole TE, Hellmann J, Wheat L, et al. Episodic exposure to fine particulate air pollution decreases circulating levels of endothelial progenitor cells. Circ Res. 2010;107:200–3. Scholar
  102. 102.
    Niu J, Liberda EN, Qu S, et al. The role of metal components in the cardiovascular effects of PM2.5. PLoS One. 2013;8:e83782. Scholar
  103. 103.
    Cui Y, Sun Q, Liu Z. Ambient particulate matter exposure and cardiovascular diseases: a focus on progenitor and stem cells. J Cell Mol Med. 2016;20:782–93. Scholar
  104. 104.
    Heida N-M, Müller J-P, Cheng I-F, et al. Effects of obesity and weight loss on the functional properties of early outgrowth endothelial progenitor cells. J Am Coll Cardiol. 2010;55:357–67. Scholar
  105. 105.
    Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781–6.CrossRefGoogle Scholar
  106. 106.
    Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45:1449–57. Scholar
  107. 107.
    Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–7.CrossRefGoogle Scholar
  108. 108.
    Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9:1370–6. Scholar
  109. 109.
    Lin C-P, Lin F-Y, Huang P-H, et al. Endothelial progenitor cell dysfunction in cardiovascular diseases: role of reactive oxygen species and inflammation. Biomed Res Int. 2013;2013:845037. Scholar
  110. 110.
    Bigarella CL, Liang R, Ghaffari S. Stem cells and the impact of ROS signaling. Development. 2014;141:4206–18. Scholar
  111. 111.
    Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation. 2003;108:3122–7. Scholar
  112. 112.
    Zhang L, Issa Bhaloo S, Chen T, et al. Role of resident stem cells in vessel formation and arteriosclerosis. Circ Res. 2018;122:1608–24. Scholar
  113. 113.
    Wong MM, Chen Y, Margariti A, et al. Macrophages Control vascular stem/progenitor cell plasticity through tumor necrosis factor-α-mediated nuclear factor-κB activation. Arterioscler Thromb Vasc Biol. 2014;34:635–43. Scholar
  114. 114.
    Tsai T-N, Kirton JP, Campagnolo P, et al. Contribution of stem cells to neointimal formation of decellularized vessel grafts in a novel mouse model. Am J Pathol. 2012;181:362–73. Scholar
  115. 115.
    Torsney E, Xu Q. Resident vascular progenitor cells. J Mol Cell Cardiol. 2011;50:304–11. Scholar
  116. 116.
    Tousoulis D, Antoniades C, Tentolouris C, et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis. 2003;170:261–7.CrossRefGoogle Scholar
  117. 117.
    van Herpen-Broekmans WMR, Klöpping-Ketelaars IAA, Bots ML, et al. Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. Eur J Epidemiol. 2004;19:915–21.CrossRefGoogle Scholar
  118. 118.
    Rashidi B, Hoseini Z, Sahebkar A, Mirzaei H. Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J Cell Physiol. 2017;232:2968–76. Scholar
  119. 119.
    Badimon L, Padró T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Hear journal Acute Cardiovasc care. 2012;1:60–74. Scholar
  120. 120.
    Gonzalez ER. Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther. 1998;20(Suppl B):B18–41.CrossRefGoogle Scholar
  121. 121.
    Mekaj YH, Daci FT, Mekaj AY. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag. 2015;11:1449–56. Scholar
  122. 122.
    Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost. 2005;3:1577–89. Scholar
  123. 123.
    Savi P, Herbert J-M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005;31:174–83. Scholar
  124. 124.
    Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008;42:550–7. Scholar
  125. 125.
    Giordano A, Musumeci G, D’Angelillo A, et al. Effects of glycoprotein iib/iiia antagonists: anti platelet aggregation and beyond. Curr Drug Metab. 2016;17:194–203.CrossRefGoogle Scholar
  126. 126.
    Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–13. Scholar
  127. 127.
    Gresele P, Momi S. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. Handb Exp Pharmacol. 2012;287–309. Scholar
  128. 128.
    Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev. 2006;24:148–68. Scholar
  129. 129.
    Gayle RB, Maliszewski CR, Gimpel SD, et al. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest. 1998;101:1851–9. Scholar
  130. 130.
    Wiysonge CS, Volmink J, Opie LH. Beta-blockers and the treatment of hypertension: it is time to move on. Cardiovasc J Afr. 2007;18:351–2.PubMedPubMedCentralGoogle Scholar
  131. 131.
    Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. Semin Nephrol. 2015;35:125–36. Scholar
  132. 132.
    Herman LL, Bhimji SS. Angiotensin Converting Enzyme Inhibitors (ACEI); 2018.Google Scholar
  133. 133.
    Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442–9.CrossRefGoogle Scholar
  134. 134.
    Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597–605. Scholar
  135. 135.
    Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65. Scholar
  136. 136.
    Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77:247–53.CrossRefGoogle Scholar
  137. 137.
    Ridker PM. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation. 2002;105:2583–5.CrossRefGoogle Scholar
  138. 138.
    Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–5.CrossRefGoogle Scholar
  139. 139.
    Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–8.CrossRefGoogle Scholar
  140. 140.
    Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8. Scholar
  141. 141.
    Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J. 2010;74:818–26.CrossRefGoogle Scholar
  142. 142.
    Scalia R, Stalker TJ. Microcirculation as a target for the anti-inflammatory properties of statins. Microcirculation. 2002;9:431–42. Scholar
  143. 143.
    Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239–42. Scholar
  144. 144.
    Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (London, England). 1987;2:1057–8.CrossRefGoogle Scholar
  145. 145.
    Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci. 1991;88:4651–5. Scholar
  146. 146.
    Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–35.CrossRefGoogle Scholar
  147. 147.
    Laufs U, La Fata V, Liao JK. Inhibition of 3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725–9. Scholar
  148. 148.
    Wagner AH, Köhler T, Rückschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61–9.CrossRefGoogle Scholar
  149. 149.
    Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999;10:543–59.CrossRefGoogle Scholar
  150. 150.
    Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999;19:2894–900.CrossRefGoogle Scholar
  151. 151.
    Mueck AO, Seeger H, Wallwiener D. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes. 2001;109:181–3. Scholar
  152. 152.
    Rezaie-Majd A, Prager GW, Bucek RA, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003;23:397–403. Scholar
  153. 153.
    Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–92. Scholar
  154. 154.
    Peng H, Luo P, Li Y, et al. Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1. PLoS ONE. 2013;8:e80009. Scholar
  155. 155.
    Huhle G, Abletshauser C, Mayer N, et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res. 1999;95:229–34.CrossRefGoogle Scholar
  156. 156.
    Hale LP, Craver KT, Berrier AM, et al. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol. 1998;18:1643–6.CrossRefGoogle Scholar
  157. 157.
    Lacoste L, Lam JY, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172–7.CrossRefGoogle Scholar
  158. 158.
    Park A, Barrera-Ramirez J, Ranasinghe I, et al. Use of statins to augment progenitor cell function in preclinical and clinical studies of regenerative therapy: a systematic review. Stem Cell Rev. 2016;12:327–39. Scholar
  159. 159.
    Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391–7. Scholar
  160. 160.
    Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933–9. Scholar
  161. 161.
    Hristov M, Fach C, Becker C, et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis. 2007;192:413–20. Scholar
  162. 162.
    Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical. Circulation. 2003;107:3109–16. Scholar
  163. 163.
    Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nut. Circulation. 2005;111:369–76. Scholar
  164. 164.
    Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004;116:682–92. Scholar
  165. 165.
    Lawler PR, Filion KB, Eisenberg MJ. Efficacy of exercise-based cardiac rehabilitation post-myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J. 2011;162:571–584.e2. Scholar
  166. 166.
    Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.CrossRefGoogle Scholar
  167. 167.
    Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000;133:92–103.CrossRefGoogle Scholar
  168. 168.
    Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res. 2004;12:789–98. Scholar
  169. 169.
    Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA. 2003;289:323–30.CrossRefGoogle Scholar
  170. 170.
    Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167:999–1008. Scholar
  171. 171.
    Pearson MJ, Smart NA. Effect of exercise training on endothelial function in heart failure patients: a systematic review meta-analysis. Int J Cardiol. 2017;231:234–43. Scholar
  172. 172.
    Ashor AW, Lara J, Siervo M, et al. Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials. Sports Med. 2015;45:279–96. Scholar
  173. 173.
    Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004;109:220–6. Scholar
  174. 174.
    Rehman J, Li J, Parvathaneni L, et al. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol. 2004;43:2314–8. Scholar
  175. 175.
    De Biase C, De Rosa R, Luciano R, et al. Effects of physical activity on endothelial progenitor cells (EPCs). Front Physiol. 2013;4:414. Scholar
  176. 176.
    Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005;45:1563–9. Scholar
  177. 177.
    Woods JA, Wilund KR, Martin SA, Kistler BM. Exercise, inflammation and aging. Aging Dis. 2012;3:130–40.PubMedGoogle Scholar
  178. 178.
    Chen Y-W, Apostolakis S, Lip GYH. Exercise-induced changes in inflammatory processes: implications for thrombogenesis in cardiovascular disease. Ann Med. 2014;46:439–55. Scholar
  179. 179.
    Gomez-Cabrera M-C, Domenech E, Viña J. Moderate exercise is an antioxidant: upregulation of antioxidant genes by training. Free Radic Biol Med. 2008;44:126–31. Scholar
  180. 180.
    de Sousa CV, Sales MM, Rosa TS, et al. The antioxidant effect of exercise: a systematic review and meta-analysis. Sport Med. 2017;47:277–93. Scholar
  181. 181.
    Posthuma JJ, van der Meijden PEJ, Ten Cate H, Spronk HMH. Short- and Long-term exercise induced alterations in haemostasis: a review of the literature. Blood Rev. 2015;29:171–8. Scholar
  182. 182.
    Beiter T, Fragasso A, Hudemann J, et al. Neutrophils release extracellular DNA traps in response to exercise. J Appl Physiol. 2014;117:325–33. Scholar
  183. 183.
    Beiter T, Hoene M, Prenzler F, et al. Exercise, skeletal muscle and inflammation: ARE-binding proteins as key regulators in inflammatory and adaptive networks. Exerc Immunol Rev. 2015;21:42–57.PubMedGoogle Scholar
  184. 184.
    Desai P, Williams AG, Prajapati P, Downey HF. Lymph flow in instrumented dogs varies with exercise intensity. Lymphat Res Biol. 2010;8:143–8. Scholar
  185. 185.
    Boulé NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286:1218–27.CrossRefGoogle Scholar
  186. 186.
    Röhling M, Herder C, Roden M, et al. Effects of long-term exercise interventions on glycaemic control in type 1 and type 2 diabetes: a systematic review. Exp Clin Endocrinol Diabetes. 2016;124:487–94. Scholar
  187. 187.
    Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia?: a systematic review and meta-analysis of longitudinal studies. BMC Public Health. 2014;14:510. Scholar
  188. 188.
    Laver K, Dyer S, Whitehead C, et al. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open. 2016;6:e010767. Scholar
  189. 189.
    Hernández SSS, Sandreschi PF, da Silva FC, et al. What are the benefits of exercise for Alzheimer’s disease? A systematic review of the past 10 years. J Aging Phys Act. 2015;23:659–68. Scholar
  190. 190.
    Pitkälä KH, Pöysti MM, Laakkonen M-L, et al. Effects of the finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial. JAMA Intern Med. 2013;173:894–901. Scholar
  191. 191.
    Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet (London, England). 2000;356:1627–31.CrossRefGoogle Scholar
  192. 192.
    Chu C-S, Tseng P-T, Stubbs B, et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8:5804. Scholar
  193. 193.
    Zissimopoulos JM, Barthold D, Brinton RD, Joyce G. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 2017;74:225–32. Scholar
  194. 194.
    Koelwyn GJ, Quail DF, Zhang X, et al. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer. 2017;17:620–32. Scholar
  195. 195.
    Demierre M-F, Higgins PDR, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930–42. Scholar
  196. 196.
    Mei Z, Liang M, Li L, et al. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017;140:1068–81. Scholar
  197. 197.
    Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ. 2016;354:i3857.CrossRefGoogle Scholar
  198. 198.
    Al-Zahrani MS, Borawski EA, Bissada NF. Periodontitis and three health-enhancing behaviors: maintaining normal weight, engaging in recommended level of exercise, and consuming a high-quality diet. J Periodontol. 2005;76:1362–6. Scholar
  199. 199.
    Estanislau IMG, Terceiro IRC, Lisboa MRP, et al. Pleiotropic effects of statins on the treatment of chronic periodontitis–a systematic review. Br J Clin Pharmacol. 2015;79:877–85. Scholar
  200. 200.
    Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–83. Scholar
  201. 201.
    Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66:142–52. Scholar
  202. 202.
    Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism. 2017;71:17–32. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hannover Medical SchoolHannoverGermany

Personalised recommendations